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Summary
Altered lipid metabolism is increasingly recognized as a signature of cancer cells. Enabled by
label-free Raman spectromicroscopy, we performed quantitative analysis of lipogenesis at single
cell level in human patient cancerous tissues. Our imaging data revealed an unexpected, aberrant
accumulation of esterified cholesterol in lipid droplets of high-grade prostate cancer and
metastases. Biochemical study showed that such cholesteryl ester accumulation was a
consequence of loss of tumor suppressor PTEN and subsequent activation of PI3K/AKT pathway
in prostate cancer cells. Furthermore, we found that such accumulation arose from significantly
enhanced uptake of exogenous lipoproteins and required cholesterol esterification. Depletion of
cholesteryl ester storage significantly reduced cancer proliferation, impaired cancer invasion
capability, and suppressed tumor growth in mouse xenograft models with negligible toxicity.
These findings open opportunities for diagnosing and treating prostate cancer by targeting the
altered cholesterol metabolism.
Introduction
Cancer cells adopt metabolic pathways that differ from their normal counterparts by high
rates of glycolysis and biosynthesis of essential macromolecules to fuel rapid growth
(Schulze and Harris, 2012). Among dysregulated metabolic pathways, increased de novo
synthesis of lipids has become a common characteristic of human cancers (Santos and
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Schulze, 2012). For instance, fatty acid synthase, the key enzyme that catalyzes the terminal
steps in fatty acid synthesis, is frequently upregulated in human malignancies and plays
important roles in cancer pathogenesis (Menendez and Lupu, 2007; Migita et al., 2009). In
parallel with lipogenesis, lipolysis has also been shown to be elevated in multiple human
cancers (Nomura et al., 2010). Specifically, monoacylglycerol lipase, the lipolytic enzyme
that hydrolyzes monoacylglycerols to release free fatty acids, was found to be overexpressed
in aggressive cancer cells. Based on the findings of upregulated expressions of both
lipogenic and lipolytic enzymes, it is conceivable that cancer cells require reservoirs for
lipids, namely lipid droplets (LDs), to store newly synthesized lipids on one hand and
provide lipids for hydrolysis on the other hand. Indeed, as early as the 1970s, LDs were
reported in clinical studies of mammary carcinoma (Ramos and Taylor, 1974). Since then,
lipid accumulation has been described in many types of human cancers, including breast,
brain, colon and others (Accioly et al., 2008; Hakumäki and Kauppinen, 2000; Rosen,
2008). Nonetheless, lipid accumulation has not, to date, been used as a prognostic factor or
therapeutic target of cancer. In particular, because compositions of LDs are not readily
accessible with traditional methods, the exact role of lipid accumulation in cancer
progression remains elusive.
LDs are visualized mainly through labeling with lipophilic dyes, which lacks compositional
information. To assay for lipid composition, analytical tools, such as mass spectrometry and
nuclear magnetic resonance spectroscopy, are commonly used. Because such techniques
analyze tissue homogenates, it is impossible to obtain compositional information of
individual LDs inside cells. The recently developed coherent Raman scattering microscopy
(Cheng and Xie, 2012) has shed new light on the study of LD biology (Le et al., 2010;
Zumbusch et al., 2013), with its label-free detection capability, high imaging speed, and
submicron spatial resolution. Using this technique, high-speed vibrational imaging of LD
dynamics in live cells and embryos has been demonstrated (Dou et al., 2012; Hellerer et al.,
2007; Lyn et al., 2010; Nan et al., 2006; Paar et al., 2012). Multiplex coherent anti-Stokes
Raman scattering microscopy has been used to study phase separation in LDs of 3T3-L1
cells (Rinia et al., 2008). Raman spectromicroscopy, which combines the high-speed
imaging capability of coherent Raman scattering microscopy and the full spectral analysis
capability of spontaneous Raman spectroscopy, allowed quantitation of not only the amount,
but also the composition, of individual LDs in live cells (Slipchenko et al., 2009).
Here, we report quantitative analysis of lipogenesis at the single cell level in intact tissues
from a spectrum of human prostate pathologies. Our label-free Raman spectromicroscopy
study revealed an unexpected accumulation of cholesteryl ester (CE) in high-grade and
metastatic human prostate cancer (PCa) tissues, but not in normal prostate, benign prostatic
hyperplasia (BPH), prostatitis, or prostatic intraepithelial neoplasia (PIN) tissues. Our
biochemical study further showed that such CE accumulation was induced by loss of tumor
suppressor PTEN, upregulation of PI3K/AKT/mTOR pathway, and consequent activation of
sterol regulatory element-binding protein (SREBP) and low-density lipoprotein receptor
(LDLr). Inhibition of cholesterol esterification significantly suppressed cancer proliferation,
migration, invasion, and tumor growth in vivo. These data collectively herald the potential of
using CE as a marker for diagnosis of aggressive PCa and open a way of treating advanced
PCa by targeting the altered cholesterol metabolism.
Results
Aberrant accumulation of esterified cholesterol in advanced human PCa revealed by
Raman spectromicroscopy
We examined a spectrum of human prostate pathologies, including normal prostate from
healthy donors and normal adjacent tissues from PCa patients (n = 19), BPH (n = 10),
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prostatitis (n = 3), PIN (n = 3), low-grade (Gleason grade 3, n = 12) and high-grade (Gleason
grade 4 or 5, n = 12) PCa from patients who had not received hormone therapy, and
metastases (n = 9) from patients who had failed hormone therapy. By tuning the laser
beating frequency to be resonant with C-H stretching vibration, substantial stimulated
Raman loss (SRL) signals arose from the lipid-rich cell membranes and intracellular LDs,
whereas weak SRL signals were derived from the lipid-poor cell nuclei. Morphologically,
the SRL images provided identical information as hematoxylin and eosin-stained slides. In
normal prostate (Figures 1A and S1A), BPH (Figure S1B), and PIN (Figure S1C), single
layers of epithelial cells facing large lumens were identified by SRL imaging. In cancerous
specimens, the SRL signals revealed small glandular structures in low-grade PCa (Figure
1B) and cell clusters without any glandular structures in high-grade PCa (Figure 1C). SRL
image of metastasis is shown in Figure 1D. All diagnoses were confirmed by pathologic
assessment of the neighboring slices stained with hematoxylin and eosin (Figures 1E–H and
S1D–F). By combining SRL with two-photon fluorescence on the same microscope, we
found that the intracellular granules present in normal prostate (Figures 1I and S1G), BPH
(Figure S1H), and PIN (Figure S1I) expressed both SRL and fluorescence signals, which
peaked at 520 nm (Figure S1J). These autofluorescent granules were consistently seen in all
19 normal prostates, 10 BPH, and 3 PIN lesions (Table S1), and were determined to be
lipofuscin according to previous reports on pigments in benign prostate (Ablin et al., 1973).
No LDs or autofluorescent granules were observed in prostatitis specimens (Figure S1K–
M). In contrast, with the exception of 4 borderline cases, the 20 primary PCa and all 9
metastases contained significant amount of LDs but no autofluorescent granules (Figure 1J–
L and Table S1). By large-area mapping and quantitation, the area fraction of LDs in human
PCa tissues was found to be 0.78 ± 0.65% for low-grade PCa, 3.93 ± 1.74% for high-grade
PCa, and 2.76 ± 1.19% for metastatic PCa (Figure 1M and Table S1). The high-grade PCa
has significantly higher LD area fraction by ~5 folds (p = 8.9E–5) compared to low-grade
PCa.
To evaluate the lipid composition, we performed confocal Raman spectral analysis of
individual autofluorescent granules or LDs accumulated in each lesion type. Figure 1N
shows representative spectra collected from normal prostate, low-grade PCa (Gleason grade
3), high-grade PCa (Gleason grade 4), metastatic PCa (liver), and pure cholesteryl oleate.
The autofluorescent granules seen in normal prostate consistently showed bands for lipid
(1200–1800 cm−1), phenylalanine (~1000 cm−1), and prominent CH3 stretching (~2930
cm−1), but lacked the characteristic C=O ester stretching band at 1742 cm−1 (Figure S1N).
These data suggest that the autofluorescent granules are primarily composed of unesterified
lipids and proteins. Similar Raman profiles were seen in both BPH and PIN lesion (Figure
S1O). Importantly, the spectra of intracellular LDs in low-grade, high-grade, and metastatic
PCa (Figure 1N) were distinctly different from those collected in normal prostate, BPH, and
PIN lesions, but nearly identical to the spectrum of pure cholesteryl oleate, with
characteristic bands for cholesterol rings at 428, 538, 614 and 702 cm−1 and for ester bond at
1742 cm−1 (Movasaghi et al., 2007). Spectra taken from various LDs in the same cancer
specimen were nearly identical (Figure S1P), which allowed quantitation of CE percentage.
Given that neutral lipids in LDs are predominantly triacylglycerol (TG) and CE (Farese and
Walther, 2009), we recorded Raman spectra of mixed emulsions containing cholesteryl
oleate and glyceryl trioleate (Figure S1Q). We found that the height ratio between the most
prominent cholesterol band at 702 cm−1 and the CH2 bending band at 1442 cm−1 was
linearly proportional to the molar percentage of CE present in the total lipids (Figure S1R).
Based on this calibration curve, we found that LDs were ubiquitously rich in CE in all stages
of PCa, specifically 90.2 ± 9.1 % for low-grade, 90.6 ± 4.9 % for high-grade, and 70.3 ±
18.5 % for metastasis (Figure 1O and Table S1). Electrospray ionization mass spectrometry
analysis of extracted lipids from tissues confirmed that CE accumulated in high-grade PCa,
but not in normal prostate. The mass data further showed that cholesteryl oleate (CE 18:1)
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was the dominant species (Figure S1S). To complete the analysis, we measured TG levels
by enzymatic assay, and did not find significant difference between the cancer tissue (0.77 ±
0.10 mg per gram of tissue) and the normal one (0.78 ± 0.02 mg per gram of tissue). Taken
together, our analyses indicate that CE is the dominant form of neutral lipids accumulated in
human PCa tissues, and it presents a promising molecular marker to improve the current
PCa diagnosis.
CE accumulation in PCa is not correlated with androgen signaling
Because androgen receptor (AR) remains transcriptionally active in castration-resistant PCa
(Debes and Tindall, 2004), and cholesterol is the precursor of the entire androgen synthesis
cascade, we first speculated that CE accumulation was associated with androgen signaling in
PCa. To test this hypothesis, we examined the LDs in non-transformed human prostate
epithelium and a panel of human PCa cells (Figure 2A, B), with various AR status and
androgen dependence (Table S2). As shown in Figure 2C, the LDs in non-transformed
prostate RWPE1 cells showed a low CE level (< 20%), and the CE level remained low upon
addition of 10% fetal bovine serum (Figure S2A). For AR-negative cancer cells, we
examined bone metastasis-derived PC-3 and brain metastasis-derived DU145, and found
that CE level was high in PC-3 (> 90%) but low in DU145 (< 20%). For AR-positive cancer
cells, we used low passage LNCaP (LNCaP-LP) and high passage LNCaP (LNCaP-HP) as
models for PCa progression (Igawa et al., 2002). The CE level was high (> 80%) in the
androgen-independent LNCaP-HP, but low (< 20%) in the androgen-dependent LNCaP-LP.
Notably, it was reported that LD accumulation in LNCaP-LP was due to the upregulation of
fatty acid synthase (Swinnen et al., 1997; Swinnen et al., 1996). Our data showed a dramatic
increase of CE levels during progression of LNCaP cells from androgen-dependent to
androgen-independent stage. Meanwhile, a key step of androgen signaling, nuclear
translocation of AR, was seen in CE-poor LNCaP-LP cells but not in CE-rich LNCaP-HP
cells (Figure 2D). Finally, we found, in AR-positive and androgen-independent C4-2 and
22Rv-1 cells, that CE level was low (< 20%) in C4-2 (Figure 2C) and LD accumulation
remained low upon dihydrotestosterone treatment in 22Rv-1 (Figure S2B). These data
collectively imply that CE accumulation may be linked to a pathway that is independent of
androgen signaling.
CE accumulation is driven by loss of PTEN and consequent upregulation of PI3K/AKT/
mTOR/SREBP pathway
The finding that CE accumulated in PC-3 cells (PTEN null) but not in DU145 cells (PTEN
wild type) then triggered us to ask whether CE accumulation resulted from loss of tumor
suppressor PTEN, which is known to activate a pathway bypassing the AR (Debes and
Tindall, 2004). Loss of PTEN has been widely observed in both localized and metastatic
PCa and is correlated with high Gleason grade (McMenamin et al., 1999). With PTEN loss,
PI3K signaling is hyperactivated, which leads to AKT activation. The upregulated PI3K/
AKT pathway has been implicated in carcinogenesis and metastasis of PCa (Sarker et al.,
2009; Vivanco and Sawyers, 2002). To determine the extent to which PTEN is involved, we
first reintroduced wild-type PTEN into PC-3 cells (Figure S3A) and found CE levels were
significantly reduced (Figure 3A). Then, we inhibited PTEN by the inhibitor BPV in DU145
cells, and found a significant increase in CE levels (Figure 3B). Because BPV is not
sufficiently specific to abrogate PTEN, we stably knocked down PTEN using shRNA in
DU145 cells. As expected, PTEN knockdown resulted in a significant reduction of PTEN
expression level and a significant increase in AKT phosphorylation (Figure 3C). We then
analyzed the LDs in the PTEN knockdown DU145 cells (Figure S3B), and found a
significant increase in CE levels (Figure 3D). In consistency, we found higher expression
levels of p-AKT in CE-rich PCa cells (PC-3 and LNCaP-HP) compared to CE-poor PCa
cells (LNCaP-LP, C4-2, and DU145) (Figure S3C). To determine the role of the PI3K/AKT/
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mTOR pathway in regulating CE accumulation, we treated both PC-3 and LNCaP-HP cells
with LY294002 (a selective PI3K inhibitor), MK2206 (a selective AKT inhibitor), and
rapamycin (a selective mTOR inhibitor), respectively. SRL imaging (Figure S3D) showed
that total LD amounts were not markedly reduced upon inhibitor treatments (Figure 3E).
Spectral analysis (Figure S3E), however, showed that CE levels were significantly reduced
in PC-3 cells (Figure 3E). The inhibition of PI3K/AKT/mTOR pathway significantly
reduced both LD amount (Figure S3F) and CE levels (Figure S3G) in LNCaP-HP cells.
Taken together, these results suggest that CE accumulation is driven by the loss of PTEN
and consequent upregulation of PI3K/AKT pathway.
It is known that AKT mediates the activation of mTOR complex 1 that plays a critical role
in regulating the function of SREBPs (Porstmann et al., 2008). The SREBPs are
transcription factors that function to control lipid and cholesterol homeostasis by sensing
cellular cholesterol (Brown and Goldstein, 1997). Increased activation of SREBPs was
found in advanced PCa (Ettinger et al., 2004). Using RNA interference, we found that
knockdown of both SREBP-1 and -2 (Figure S3H) led to significantly reduced CE levels in
PC-3 cells without affecting LD amount, and knockdown of SREBP-1 resulted in a stronger
effect than knockdown of SREBP-2 (Figure 3E). Using immunoblotting, we further found
that inhibition of the PI3K/AKT/mTOR pathway significantly suppressed both the
expression level and cleavage of SREBP-1 in PC-3 cells (Figure 3F), indicating that CE
accumulation is closely related to the activity of SREBP-1 isoforms. These results
collectively show an essential role of SREBP in regulating CE accumulation.
CE accumulation in PCa cells arises from enhanced uptake of exogenous LDL
Because cholesterol can be either de novo synthesized via the mevalonate pathway or taken
up from exogenous lipoproteins, we investigated the source of cholesterol used for CE
accumulation. We first treated PC-3 cells with simvastatin, an inhibitor of 3-hydroxy-3-
methylglutaryl coenzyme A reductase, the rate-limiting enzyme of the mevalonate pathway.
As shown in Figure 4A, simvastatin neither decreased LD amount nor significantly reduced
CE levels. In contrast, after treating cells with lipoprotein-deficient serum, LDs nearly
disappeared in CE-rich PC-3 cells (Figure 4B), but remained the same amount in CE-poor
cells, including LNCaP-LP, DU145, and C4-2 (Figure S4A, B). Re-addition of LDL into the
lipoprotein-deficient medium restored the LD amount (Figure 4B) with a CE level of 93.6 ±
5.5 % in PC-3 cells. By treating cells with DiI-labeled LDL, it was found that LDL uptake
was the most prominent in the CE-rich PC-3 cells compared to CE-poor PCa cells (Figure
S4C, D). Inhibition of the PI3K/AKT/mTOR pathway significantly reduced expression
levels of LDLr (Figure 4C), and blocked the uptake of DiI-labeled LDL in PC-3 cells
(Figure 4D). Knockdown of SREBP using siRNA also reduced the LDL uptake in PC-3
cells (Figure 4E). These results collectively support that CE accumulation in PCa cells is a
consequence of enhanced uptake of LDL.
CE accumulation in PCa cells requires cholesterol esterification by ACAT-1
LDL is known to enter a cell via LDLr and traffic to the late endosome and lysosome to be
hydrolyzed to free fatty acids and free cholesterol. The excess free cholesterol together with
the fatty acyl CoA substrate is then converted to CE by acyl coenzyme A: cholesterol
acyltransferase (ACAT) and stored in LDs (Chang et al., 2006). Thus, we treated cells
separately with avasimibe and Sandoz 58-035, two different ACAT inhibitors. Both
avasimibe (Figure 4F) and Sandoz 58-035 (Figure S4E) effectively suppressed CE
accumulation in PC-3 cells, with the amount of LDs slightly decreased (Figure 4F). The
significant reduction of CE accumulation upon avasimibe treatment was verified by
biochemical assay (Figure S4F) and mass spectrometry of extracted lipids from PC-3 cells
(Figure S4G). The mass data (Figure 4G) further showed that cholesteryl oleate (CE 18:1)
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was the dominant species present. Because ACAT inhibitors inhibits both ACAT-1 and -2
isoforms, we knocked down ACAT-1 using shRNA (Figure S4H), and found significant
reduction of the CE level in PC-3 cells (Figure 4F). In addition, inhibition of PI3K/AKT/
mTOR pathway significantly reduced expression levels of ACAT-1 (Figure 4C). These
results collectively confirm the involvement of ACAT-1 in CE storage in PCa cells.
Depletion of CE storage impairs PCa aggressiveness
Because CE accumulation was found in PCa but was not detectable in normal prostate, we
evaluated how cell viability could be affected by regulating CE levels. Separate treatments
by avasimibe (Figure 5A) and Sandoz 58-035 (Figure S5A) significantly reduced viability of
PC-3 cells, with IC50 value of 7.3 μM and 17.2 μM, respectively. Avasimibe treatment also
significantly reduced viability of LNCaP-HP cells, with IC50 value of 9.6 μM (Figure S5B).
The inhibitory effect of avasimibe on the growth of non-transformed RWPE1 cells and CE-
poor PCa cells, including LNCaP-LP, DU145, and C4-2, was considerably smaller than that
in PC-3 and LNCaP-HP cells (Figure S5C). To confirm the inhibitory effect was ACAT-1
specific, we knocked down ACAT-1 using shRNA, and observed significantly reduced
viability in PC-3 cells (Figure S5D). Results from flow cytometry analysis (Figure 5B)
revealed that exposure of PC-3 cells to avasimibe resulted in both cell cycle arrest and
apoptosis, i.e. the G2/M phase population was ~2 times smaller whereas the sub-G1
population was ~3 times larger in avasimibe-treated group compared to control group.
Because the lipids in LDs are primarily composed of CE and TG, we treated PC-3 cells with
a selective inhibitor of diacylglycerol acyltransferase (DGAT)-1, which catalyzes the
terminal step of TG formation. Our data showed that DGAT inhibition by A922500 did not
affect cell viability until high doses (Figure S5A).
To evaluate whether CE depletion affects tumor aggressiveness, we conducted standard
transwell assays (Figure S5E). Our results showed that both migration and invasion
capabilities of PC-3 cell were markedly suppressed upon ACAT inhibition by avasimibe or
Sandoz 58-035, and ACAT-1 knockdown using shRNA (Figure 5C). In contrast, DGAT
inhibition slightly increased PC-3 cell migration (Figure S5F) and invasion (Figure S5G). As
a positive control, PTEN knockdown in DU145 cells led to significantly greater capabilities
of growth (Figure S5H), migration and invasion (Figure 5D), compared to the CE-poor
PTEN wild-type DU145 cell. This result is consistent with the previous study (Dubrovska et
al., 2009), where PTEN knockdown led to increased clonogenic and tumorigenic potential of
DU145 cell. Importantly, ACAT inhibition by avasimibe significantly suppressed viability
(Figure S5H), migration and invasion capabilities (Figure 5D) of PTEN knockdown DU145
cells. These results collectively show that CE depletion suppresses aggressiveness of CE-
rich PCa cells in vitro.
To test the potential of treating advanced PCa in vivo by ACAT inhibition, we separately
administered avasimibe and Sandoz 58-035 (15 mg/kg) to athymic nude mice bearing PC-3
xenografts. Daily treatment of mice with avasimibe inhibited the growth of PC-3 tumors by
~2 fold (Figure 5E), and significantly reduced weight of tumor tissues (Figure 5F). Similar
results were observed from the mice treated with Sandoz 58-035 (Figure S5I, J). In contrast,
daily treatments of mice with DGAT inhibitor A922500 (3 mg/kg) did not reduce PC-3
growth in vivo (Figure S5I, J). To confirm the efficacy of ACAT inhibition in tumors with
inactivated PTEN, we transplanted the stable PTEN knockdown DU145 cells into mice. The
results showed that ACAT inhibition by avasimibe suppressed the growth of PTEN
knockdown DU145 tumors by ~4 fold (Figure 5G), and reduced weight of tumor tissues by
~3 fold (Figure 5H). Importantly, the ACAT inhibitors did not cause general toxicity to
animals, as indicated by no changes in body weight observed in the mice treated with
avasimibe (Figure 5I, J) or Sandoz 58-035 (Figure S5K). Pathological review of sections of
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heart, kidney, liver, lung, and spleen harvested from mice receiving avasimibe showed no
detectable signs of toxicity (Figure S5L). Spectroscopic analysis of extracted tissues
revealed that CE levels significantly dropped in avasimibe-treated tumors compared to
vehicle-treated ones (Figure 5K), even though LD area fraction was not affected (Figure
S5M), indicating that ACAT inhibitor worked to inhibit CE formation in tumor cells in vivo.
Immunohistochemistry using markers for proliferation (Ki67) and apoptosis (TUNEL)
(Figure S5L) showed that avasimibe significantly reduced tumor proliferation by ~70% and
increased apoptosis by ~2 fold (Figure 5L).
CE depletion impairs PCa growth by limiting uptake of essential fatty acids
We first suspected that CE storage might act as a pool of fatty acid and cholesterol which
can be released from LDs for cancer cell proliferation. The result that inhibition of CE
hydrolysis using diethylumbelliferyl phosphate, a selective cholesterol esterase inhibitor,
slightly enhanced PC-3 cell growth (Figure S6A) did not support such hypothesis. We then
asked whether CE depletion suppressed PCa proliferation by downregulation of the
upstream pathways including LDL uptake. We notice that LDL is the primary carrier of
essential polyunsaturated fatty acids, including arachidonic acid (AA) (Habenicht et al.,
1990). Inside cells, AA is released from LDL and converted to a range of eicosanoids that
have been implicated in various pathological processes, including inflammation and cancer
(Wang and Dubois, 2010). Because cholesterol esterification is known to play a vital role in
maintaining intracellular cholesterol homeostasis (Chang et al., 2006), we hypothesized that
abrogating ACAT activity can inhibit PCa growth by elevating free cholesterol levels,
downregulating expression levels of SREBP and LDLr, and consequently reducing the
uptake of LDL. To test this hypothesis, we measured free cholesterol levels in PC-3 cells
with a biochemical assay and found that avasimibe treatment significantly increased the free
cholesterol levels (Figure 6A). Moreover, knockdown of ACAT-1 (Figure 6B) or inhibition
of ACAT using avasimibe (Figure 6C) or Sandoz 58-035 (Figure S6B) resulted in reduced
expression levels of SREBP-1 and LDLr and also reduced SREBP-1 cleavage.
Quantification of the western blots further confirmed that expression levels of both
precursor and cleaved forms of SREBP-1 were significantly reduced upon ACAT-1
knockdown or inhibition (Figure S6C). The LDLr expression level in implanted PC-3 tumor
was also reduced in avasimibe-treated group compared to the vehicle group (Figure S6D).
By monitoring cellular uptake of DiI-LDL, we found that avasimibe treatment resulted in
reduced LDL uptake by ~10 fold (Figure 6D). Furthermore, liquid chromatography-mass
spectrometry analysis of PC-3 cell lysates revealed that avasimibe treatment or ACAT-1
knockdown significantly reduced the level of AA in PC-3 cells (Figure 6E) and LNCaP-HP
cells (Figure S6E). As shown elsewhere (Ghosh and Myers, 1997; Hughes-Fulford et al.,
2001) and confirmed herein, AA (Figure 6F) and LDL (Figure S6F) separately promoted the
growth of PC-3 cells in a dose-dependent manner. AA was also shown to rescue the
inhibitory effect of avasimibe on PC-3 cell viability (Figure 6G). Moreover, expression
levels of p-AKT were significantly reduced in PC-3 cells upon ACAT-1 knockdown (Figure
6B) or avasimibe treatment (Figure 6C). This reduction is consistent with the role of AA as
an activator of PI3K/AKT signaling in PCa (Hughes-Fulford et al., 2006). These data
collectively provide evidence that ACAT inhibition might hinder proliferation of CE-rich
PCa cells by limiting the uptake of a critical proliferative factor, AA, via downregulation of
LDLr.
Discussion
Through integrated analyses of PCa clinical samples, cell lines, and mouse xenograft model,
we have revealed an essential role of CE, a lipid metabolite, in human PCa progression. CE
accumulation is known to be a hallmark of atherosclerosis and hormone-producing organ
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(Farese and Walther, 2009; Murphy, 2001), however its exact role in cancer progression
remains elusive. In this study, prominent CE accumulation that only occurs in advanced PCa
is shown to be a consequence of the loss of tumor suppressor PTEN and subsequent
activation of PI3K/AKT/mTOR pathway. Blockage of CE accumulation significantly
impairs PCa aggressiveness without inducing toxicity to normal cells. As discussed below,
these findings improve current understanding of the role of cholesterol in cancer and also
open opportunities for treatment of aggressive PCa.
First, our study extends current understanding of metabolic pathways that drive PCa
progression. Increasing evidence supports that androgen signaling pathways remain active
throughout every stage of PCa progression (Debes and Tindall, 2004). However, expression
levels of AR are heterogeneous and even absent in some metastases (Shah et al., 2004).
Such clinical observations suggest that PCa cells may also depend on other compensatory
signaling pathways to survival and grow. One of the most important pathways that bypass
AR is the PI3K/AKT/mTOR pathway, which is negatively regulated by the tumor
suppressor PTEN. PTEN has been identified as one of the most commonly lost or mutated
tumor suppressor genes in human cancers (Chalhoub and Baker, 2009). In particular, nearly
70% of advanced PCa exhibit loss of PTEN or consequent activation of the PI3K/AKT
pathway (Mulholland et al., 2011), which leads to enhanced cell survival, metastasis, and
castration-resistant growth (Liu et al., 2011; Mulholland et al., 2011; Vivanco and Sawyers,
2002). Our results, as illustrated in Figure 7, show that PTEN loss induces CE accumulation
by upregulating the PI3K/AKT/mTOR pathway and subsequently activating SREBP and
LDLr. This finding elucidates the mechanism by which PTEN regulates metabolic pathways
to meet the increased demand of aggressive PCa cell for LDL cholesterol uptake. Our study
further shows that such enhanced LDL uptake is linked to AA. Increasing evidence has
shown that one key risk factor of PCa is dietary fat (Kolonel et al., 1999), particularly the
high ω6/ω3 fatty acid ratio (Kobayashi et al., 2006). These findings are consistent with our
data about AA-enhanced PCa growth.
Whereas alterations to metabolism of glucose, amino acids, and fatty acids have been
extensively studied (Schulze and Harris, 2012), cholesterol metabolism in cancer is a
relatively understudied field (Santos and Schulze, 2012). Inside cells, cholesterol is an
essential molecule that plays important roles in the maintenance of membrane structure,
signal transduction, and provision of precursor to hormone synthesis (Ikonen, 2008). As
early as 1942, increased level of free cholesterol in the adenoma of enlarged prostates was
reported by analysis of tissue homogenates (Swyer, 1942). More recently,
immunohistochemical staining of PCa bone metastases showed intense staining of the LDLr
(Thysell et al., 2010), which supports the important role of LDL uptake in PCa progression.
However, the molecular mechanisms by which advanced PCa cells obtain sufficient
cholesterol and in the meanwhile maintain intracellular cholesterol homeostasis remain
poorly understood. Our imaging study of human tissues identified a possible culprit, that is,
accumulation of esterified cholesterol in LDs of advanced PCa cells. Advanced PCa cells
take advantage of the esterified form not only to avoid toxicity of excess cholesterol (Chang
et al., 2006), but also to keep free cholesterol at relatively low level so that SREBP, which
controls cholesterol biogenesis, is always active. This mechanism explains why PCa cells
could maintain high expression levels of LDLr even in the presence of exogenous
cholesterol (Chen and Hughes-Fulford, 2001). Although it is known that LDLr gene
transcription is under the control of SREBP-2 in the liver, it has also been reported that
LDLr is responsive to SREBP-1 (Horton et al., 2003; Sekar and Veldhuis, 2004; Yokoyama
et al., 1993), specifically SREBP-1a, in certain contexts including glioblastoma (Guo et al.,
2011). Our result that ACAT inhibition leads to reduced levels of SREBP-1 and LDLr,
together with the finding that SREBP-1 knockdown leads to reduced LDL uptake, suggest
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that SREBP-1 plays an important role in LDLr regulation in human prostate cancer PC-3
cells.
We note that statin use has been linked to a decreased risk of advanced PCa (Platz et al.,
2006), and its benefits were found to be based on systemic cholesterol-lowering effect rather
than direct effect on de novo cholesterol synthesis (Murtola et al., 2011). In accordance, our
cellular studies reveal that cholesterol stored in the LDs of advanced PCa cells is not
synthesized de novo, but rather derived from enhanced uptake of exogenous LDL. Using
mass spectrometry, we find that cholesteryl oleate is the dominant species of CE inside the
LDs. This result suggests that LDL with cholesteryl linoleate as the dominant form is
hydrolyzed into free cholesterol and then re-esterified to CE by ACAT-1. Together, our
finding offers a biological foundation that supports the beneficial effect of cholesterol-
lowering drugs.
Second, our study heralds the potential of using CE as a therapeutic target for advanced PCa.
While often diagnosed in clinically localized stages, PCa remains the second leading cause
of cancer-related mortality in American men (Siegel et al., 2012). For men with advanced
PCa, androgen deprivation therapy is an accepted standard therapy. Despite initial disease
control, androgen deprivation therapy alone is non-curative and the subsequent development
of castration-resistant PCa occurs in the lifespan of almost all men who do not succumb to
non-cancer deaths (Debes and Tindall, 2004). There has been a tremendous increase in
treatment options available for metastatic castration-resistant PCa patients, including novel
anti-androgen therapy (de Bono et al., 2011) and others. Nevertheless, the effectiveness of
current therapies is palliative with an improvement in overall survival of 2–5 months
compared to placebo. In this study, we show that CE depletion by abrogating ACAT activity
significantly hinders advanced PCa growth. One possible explanation for such anti-cancer
effect, as illustrated in Figure 7, is that depleting CE storage disrupts intracellular cholesterol
homeostasis and consequently reduces the uptake of essential fatty acids, such as AA, a
proliferation factor of PCa (Ghosh and Myers, 1997; Hughes-Fulford et al., 2001). Because
CE depletion leads to elevation of free cholesterol levels, apoptosis induced by ACAT
inhibition could be due to free cholesterol toxicity. The alteration of cholesterol metabolism
might also be linked to regulation of lipid rafts in PCa (Hager et al., 2006). Importantly, the
CE-depleting drug does not cause detectable toxicity to normal cells. Thus, cholesterol
esterification may be a cancer-specific target for developing an effective, non-toxic anti-
cancer therapy. Blockage of cholesterol esterification was used to treat cells of lymphocytic
leukaemia (Mulas et al., 2011), glioblastoma (Bemlih et al., 2010), and breast cancer
(Antalis et al., 2009) in vitro. In this work, we demonstrate its effectiveness in suppressing
growth of aggressive tumor in vivo. We note that avasimibe was previously used to treat
atherosclerosis (Llaverías et al., 2003) but failed due to the lack of effectiveness in reducing
plaque size. Together, this study offers a potentially effective way of treating advanced PCa
by abrogating ACAT-1 activity.
Finally, given that the PI3K pathway is hyperactivated not only in advanced PCa, but also in
many other human cancers, including brain, breast, renal, lymphocyte, cervical, and lung
(Luo et al., 2003), CE accumulation might be a common characteristic of PI3K-driven
cancers. Indeed, CE was found to be a proliferative factor for leukemia (Mulas et al., 2011),
and dysregulation of cholesterol metabolism was reported in glioblastoma (Guo et al., 2011).
Future elucidation of the molecular mechanisms by which the PI3K pathway differentially
regulates cholesterol metabolism in cancer cells from multiple tissues of origin will
determine whether cholesterol esterification is a compelling drug target across multiple
cancer types. Such studies will further improve current understanding of how metabolic
reprogramming is linked to oncogenic transformation.
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Experimental Procedures
Human prostate tissue specimens, cell culture, and chemicals
This study was approved by institutional review board. Frozen specimens of human prostate
tissues were obtained from Indiana University Simon Cancer Center Solid Tissue Bank and
Johns Hopkins Hospital. Cell lines were obtained from the American Type Culture
Collection. Details are described in Supplemental Experimental Procedures.
Label-free Raman spectromicroscopy
Label-free Raman spectromicroscopy was performed on unfixed and unstained tissue slices
(~ 20 μm) and live cells without any processing or labeling. SRL imaging was performed on
a femtosecond SRL microscope, with the laser beating frequency tuned to the C-H
stretching vibration band at 2845 cm−1, as described previously (Zhang et al., 2011).
Compositional analysis of individual LDs and autofluorescent granules was performed by
integration of high speed coherent anti-Stokes Raman scattering imaging and confocal
Raman spectral analysis on a single platform (Slipchenko et al., 2009). More details are
described in Supplemental Experimental Procedures.
We profiled lipogenesis in two aspects, LD amount and CE percentage in individual LDs.
By using ImageJ “Threshold” function, LDs in the cells can be selected due to their
significantly higher signal intensities compared to other cellular compartments. Then, by
using ImageJ “Analyze Particles” function, area fraction of LDs out of total image area can
be quantified. For tissue specimen, the area fractions of LDs from the two different locations
were averaged to obtain the final value of LD area fraction. For cultured cells, the area
fraction of LDs was further normalized by cell number to obtain LD amount, and ~50 cells
were analyzed. The percentage of CE in individual LDs was linearly correlated with the
height ratio of the 702 cm−1 peak to the 1442 cm−1 peak (I702/I1442). Specifically, I702/I1442
= 0.00255 × CE percentage (%) (Figure S1R). CE percentage for each specimen or cell
culture was obtained by averaging the CE percentage of LDs in 5~10 cells, given that
Raman profiles of LDs in different cells in the same specimen or cell culture were nearly the
same (Figure S1P).
Cell aggressiveness assays, cell cycle analysis, and tumor xenograft studies
Cell migration, invasion, viability, cell cycle, and tumor xenograft studies of cancer cells
were performed as described in the Supplemental Experimental Procedures. Invasion and
migration assays were performed in Transwell chambers (Corning) coated with and without
Matrigel (BD Bioscience) respectively. Cell viability assays were performed using Thiazolyl
Blue Tetrazolium Blue (MTT) colorimetric assay (Sigma). Human cancer xenografts were
established by transplanting PC-3 or PTEN knockdown DU145 cells subcutaneously into the
flank of athymic nude mice. Intraperitoneal drug injections started ~2 weeks after
implantation (day 0). Relative tumor volume = tumor volume / initial tumor volume (day 0)
for each mouse. Details are described in Supplemental Experimental Procedures.
Lipid extraction and measurements
Lipids in cells and tissues were extracted and measured as described previously (Folch et al.,
1957; Liebisch et al., 2006; Yang et al., 2007). Details are described in Supplemental
Experimental Procedures.
Immunoblotting, Immunohistochemistry, and RNA interference were performed as
described in the Supplemental Experimental Procedures.
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Statistical analysis
One-way ANOVA and Student’s t test were used for comparisons between groups and p <
0.05 was considered statistically significant. SD: standard deviation; SEM: standard error of
the mean. Details are described in the Supplemental Experimental Procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Aberrant CE accumulation in human PCa tissues
(A–D) Large-area SRL images and benign prostate, low-grade PCa (Gleason grade 3), high-
grade PCa (Gleason grade 4), and metastatic PCa (liver), respectively. (E–H) Hematoxylin
and eosin (H&E) staining of the adjacent slices. Scalar bar, 100 μm. (I–L) High
magnification SRL and two-photon fluorescence images of the lesions shown in (A-D)
(grey: SRL, green: two-photon fluorescence). Autofluorescent granules and LDs indicated
by red arrows. Scalar bar, 20 μm. (M) LD area fraction in 19 normal prostate, 10 BPH, 3
prostatitis, 9 low-grade PCa, 11 high-grade PCa, and 9 metastatic PCa. Mean of LD area
fraction indicated by red line. n.s., not significant. (N) Raman spectra of autofluorescent
granules in normal prostate, LDs in PCa, and pure cholesteryl oleate. Spectral intensity was
normalized by CH2 bending band at 1442 cm−1. Black arrows indicate the bands of
cholesterol rings at 702 cm−1. (O) CE molar percentage in LDs of low-grade PCa (n = 9),
high-grade PCa (n = 11), and metastatic PCa (n = 9). Error bars represent SD.
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Figure 2. CE accumulation is not correlated with androgen signaling
(A) SRL images of various types of cells, including RWPE1, LNCaP-LP, LNCaP-HP, PC-3,
DU145, and C4-2. LDs indicated by green arrows. (B) Raman spectra of LDs in cells shown
in (A). Spectral intensity was normalized by the peak at 1442 cm−1. Black arrows indicate
the bands of cholesterol rings at 702 cm−1. (C) Quantitation of LD amount and CE
percentage. LD amount was normalized by the RWPE1 group. Error bars represent SEM. n
> 5. **: p < 0.005, ***: p < 0.0005. (D) Nuclear translocation of androgen receptor (AR) in
LNCaP-LP and LNCaP-HP cells. Blue: DAPI, Red: AR immunofluorescence. Scalar bar, 10
μm.
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Figure 3. CE accumulation is induced by PTEN loss and PI3K/AKT activation
(A) Raman spectra of LDs in PTEN-null and PTEN-overexpressed PC-3 cells (3 day
transfection) are shown. The band of cholesterol rings at 702 cm−1 nearly disappeared after
the treatment, as indicated by the arrows. Quantitation of CE percentage and LD amount is
shown below the spectra. n > 5. (B) CE levels in DU145 cell treated with PTEN inhibitor
BPV (10 μM) for 3 days. Raman spectra of LDs in control and treated cells are shown. The
band of cholesterol rings at 702 cm−1 significantly increased after the treatment, as indicated
by the arrows. Quantitation of CE percentage and LD amount is shown below the spectra. n
> 5. Spectral intensity was normalized by the peak at 1442 cm−1 in (A, B). (C) Immunoblot
of antibodies against PTEN, p-AKT, and β-Actin in PTEN-WT and PTEN-KD DU145 cells.
(D) CE percentage and LD amount in PTEN-WT and PTEN-KD DU145 cells. (E) CE
percentage and LD amount in cells treated with DMSO as control, LY294002 (50 μM, 3
day), MK2206 (10 μM, 2 day), rapamycin (100 nM, 2 day), and SREBP-1 and -2 siRNA (2
day transfection). n > 5. LD amount was normalized by the control group in (A, B, D, E).
(F) Immunoblot of antibodies against p-AKT, p-S6, SREBP-1 and -2, and β-Actin in PC-3
cells treated with DMSO as control (Ctl), LY294002 (LY), MY2206 (MK), and rapamycin
(Rapa). P: precursor form, C: cleaved form. The expression levels of p-AKT and p-S6 were
reduced after inhibitor treatments as expected. WT: wild-type, KD: knockdown. Error bars
represent SEM. ***: p < 0.0005.
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Figure 4. CE accumulation arises from enhanced uptake of LDL and involves cholesterol
esterification by ACAT-1
(A) LD amount and CE percentage in PC-3 cells treated with or without simvastatin (10 μM,
1 day), n > 5. (B) SRL images and quantitation of LD amount in PC-3 cells treated with
lipoprotein deficient serum (LPDS, 10%, 1 day) and subsequent LDL re-addition (45 μg/ml,
1 day), n = 6. LDs indicated by the green arrow. (C) Immunoblot of antibodies against
LDLr, ACAT-1, and β-Actin in PC-3 cells treated with DMSO as control (Ctl), LY294002
(LY, 50 μM, 3 day), MK2206 (MK, 10 μM, 2 day), and rapamycin (Rapa, 100 nM, 2 day).
(D, E) Quantitation of DiI-LDL uptake by PC-3 cells treated with DMSO as control,
LY294002, and rapamycin (n = 5) (D), and transfected with SREBP-1 or -2 siRNA (n = 5)
(E). DiI-LDL intensity was normalized by the control group. (F) Raman spectra of LDs and
quantitation of LD amount and CE percentage in PC-3 cells treated with avasimibe (7.5 μM,
1 day) and ACAT-1 shRNA (3 day transfection). n > 5. Spectral intensity was normalized by
the peak at 1442 cm−1. The bands of cholesterol rings at 702 cm−1 nearly disappeared after
the treatments, as indicated by the arrows. LD amount was normalized by the control group
in (A, B, F). (G) Mass spectra of lipids extracted from control and avasimibe-treated PC-3
cells (7.5 μM, 2 day). The m/z 668 peak stands for cholesteryl oleate (CE 18:1). DiI-LDL:
Yue et al. Page 18
Cell Metab. Author manuscript; available in PMC 2015 March 04.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
DiI-labeled LDL. Error bars represent SEM. **: p < 0.005, ***: p < 0.0005. Scalar bar, 10
μm.
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Figure 5. CE depletion impairs PCa aggressiveness
(A) IC50 curve of avasimibe treatments (3 day) on PC-3 cells (IC50 = 7.3 μM). n = 6. The
control group (DMSO) was used for normalization. (B) Flow cytometry analysis of cell
cycle in control and avasimibe-treated (7.5 μM, 3 day) PC-3 cells (n = 3). PI: propidium
iodide. (C) Quantitation of migrated and invaded PC-3 cells that were pretreated with
avasimibe (5 μM), Sandoz 58-035 (10 μM), or ACAT-1 shRNA for 2 days (n = 3). The
control group was used for normalization. (D) Quantitation of migrated and invaded PTEN-
WT or PTEN-KD DU145 cells that were pretreated with DMSO as control or avasimibe (5
μM) for 1 day (n = 3). The PTEN-WT DU145 group was used for normalization. (E)
Relative tumor volume of PC-3 xenograft (n = 9) upon daily avasimibe treatments (15 mg/
kg). Representative tumors harvested on day 30 are shown in the inset. Scalar bar, 1 cm. (F)
Weight of tumor tissues harvested from vehicle and avasimibe-treated mice in (E). (G)
Relative tumor volume of PTEN-KD DU145 xenograft (n = 8). Representative tumors
harvested on day 21 are shown in the inset. Scalar bar, 1 cm. (H) Weight of tumor tissues
harvested from vehicle and avasimibe-treated mice in (G). (I, J) Body weight of the mice
bearing PC-3 tumors (n = 9) (I), and PTEN-KD DU145 tumors (n = 8) (J). (K) CE
percentage and (L) Percentage of Ki67 and TUNEL positive cells in tumor tissues harvested
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from vehicle and avasimibe-treated mice in (E) (n = 5). Ctl: control, Veh: vehicle, Ava:
avasimibe, WT: wild-type, KD: knockdown. Error bars represent SEM. *: p < 0.05, **: p <
0.005, ***: p < 0.0005.
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Figure 6. CE depletion reduces PCa cell proliferation by limiting the uptake of essential fatty
acids
(A) Free cholesterol level in control and avasimibe-treated PC-3 cells (n = 3). (B, C)
Immunoblot of antibodies against SREBP-1 and -2, LDLr, p-AKT, and β-Actin in PC-3 cells
treated with ACAT-1 shRNA (B) or avasimibe (C). P: precursor form, C: cleaved form. (D)
Quantitation and representative images and of DiI-LDL uptake in control and avasimibe-
treated PC-3 cells (n = 5). Grey: SRL; Green: two-photon fluorescence. Scalar bar, 10 μm.
DiI-LDL intensity was normalized by the control group. (E) AA levels in PC-3 cells treated
with avasimibe or ACAT-1 shRNA (n = 3). In (A-E), avasimibe treatment: 7.5 μM, 2 day,
ACAT-1 shRNA: 3 day transfection. (F) Dose-dependent growth of PC-3 cells upon AA
treatments (3 day). (G) PC-3 cell viability upon avasimibe treatment (7.5 μM) in the absence
or presence of AA (7.5 μM) for 3 day. The control groups were used for normalization. AA:
arachidonic acid, Ava: avasimibe. Error bars represent SEM. *: p < 0.05, **: p < 0.005, ***:
p < 0.0005.
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Figure 7. Molecular pathways underlying accumulation of CE in advanced human PCa and
suppression of cancer proliferation upon CE depletion
The schematic shows that loss of PTEN activates PI3K/AKT/mTOR pathway, which in turn
upregulates SREBP and LDLr. LDL is then hydrolyzed to free fatty acids and free
cholesterol (FC) in lysosome. The excess FC together with the fatty acyl CoA substrate is
converted to CE by ACAT-1 and stored in LDs. LDL also serves as an important carrier of
ω-6 polyunsaturated fatty acid (PUFA), such as AA, which promotes cell proliferation and
tumor growth. The red arrows depict the consequences of CE depletion. Depletion of CE
storage by ACAT-1 knockdown or ACAT inhibition disturbs cholesterol homeostasis by
elevating FC levels and consequently downregulating expression levels of SREBP and
LDLr. Subsequently reduced uptake of ω-6 PUFA from LDL suppresses cancer
proliferation.
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